Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are glucocorticoids DMARDs?

Johannes W J Bijlsma1, Jos N Hoes, Amalia A Van Everdingen

  • 1Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Box 85 500, 3508 GA Utrecht, The Netherlands. j.w.j.bijlsma@umcutrecht.nl

Annals of the New York Academy of Sciences
|July 21, 2006
PubMed
Summary

Low-dose glucocorticoids effectively manage rheumatoid arthritis (RA) by controlling disease activity and preventing joint damage, particularly in early stages. These findings establish glucocorticoids as valuable disease-modifying antirheumatic drugs (DMARDs) for RA treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin D supplementation: still a challenge for rheumatologists!

EULAR rheumatology open·2026
Same author

Individualised treatment effect prediction: the benefit of initial biological treatment in early rheumatoid arthritis.

EULAR rheumatology open·2026
Same author

Cracking the code of therapeutic failure in inflammatory rheumatic diseases: collaborative pathways bridging academia, industry, and patient-centric innovation.

Annals of the rheumatic diseases·2026
Same author

HandScan criteria versus ACR/EULAR Boolean remission as treatment target in early rheumatoid arthritis: results of a randomized controlled trial.

Rheumatology advances in practice·2025
Same author

In Memoriam: Alfonse T. Masi, MD.

Neuroimmunomodulation·2025
Same author

Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data.

RMD open·2024

Area of Science:

  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive damage.
  • Disease-modifying antirheumatic drugs (DMARDs) are crucial for managing RA, aiming to control disease activity and preserve joint function.
  • The role of glucocorticoids in RA treatment has been debated, with concerns about long-term side effects often outweighing their benefits.

Purpose of the Study:

  • To evaluate the efficacy of low-dose glucocorticoids in managing rheumatoid arthritis.
  • To determine if glucocorticoids can be classified as disease-modifying antirheumatic drugs (DMARDs).
  • To assess the specific benefits of glucocorticoids in early RA and in combination therapy.

Main Methods:

  • Systematic review and critical evaluation of accumulated evidence on glucocorticoid use in RA.

Related Experiment Videos

  • Analysis of studies focusing on low-dose glucocorticoid regimens.
  • Assessment of glucocorticoid impact on disease control and joint damage progression.

    • Main Results:

    • Evidence suggests low-dose glucocorticoids effectively control RA disease activity.
    • Glucocorticoids demonstrate a capacity to limit joint destruction in RA patients.
    • These benefits are particularly pronounced in early RA and when used in combination with other DMARDs.

    Conclusions:

    • Glucocorticoids, particularly at low doses, should be considered effective DMARDs for rheumatoid arthritis.
    • Their use is strongly supported in the management of early RA.
    • Glucocorticoids offer significant value in combination therapy for RA, improving long-term outcomes.